Myomics, Inc. develops drugs to treat neuromuscular disease indications, such as muscle atrophy in the elderly and muscle wasting in chronic illness, including cancer and muscular dystrophy disorders. It has discovery programs based on its two proprietary technology platforms: tissue-engineered muscle, which can be generated in vitro from human and animal models of normal and diseased muscle; and opto-mechanical systems to monitor the ability of candidate compounds to increase the contractile strength of tissue-engineered muscle.
